Literature DB >> 27342810

Trends over the past 4 years in population characteristics, 30-day outcomes and 1-year survival in patients treated with transcatheter aortic valve implantation.

Guillaume Avinée1, Eric Durand2, Safwane Elhatimi1, Fabrice Bauer1, Bastien Glinel1, Jean-Nicolas Dacher1, Guillaume Cellier1, Guillaume Viart1, Christophe Tron1, Matthieu Godin1, Pierre-Yves Litzler1, Alain Cribier1, Hélène Eltchaninoff1.   

Abstract

BACKGROUND: Transcatheter aortic valve implantation (TAVI) is recommended in patients with severe aortic stenosis that is either inoperable or at high-risk for surgical valve replacement. AIMS: To evaluate trends in the feasibility and safety of transfemoral TAVI over the past 4 years.
METHODS: Between 2010 and 2013, all consecutive patients undergoing TAVI in our institution were included in a prospective registry. Population characteristics and 30-day and 1-year outcomes were analysed. Outcomes were classified according to the Valve Academic Research Consortium-2.
RESULTS: Overall, 429 patients underwent TAVI; transfemoral access was used in 368 (85.7%). The proportion of patients treated via a transfemoral approach increased (70.1% to 89.9%; P<0.0001) and the use of prior balloon aortic valvuloplasty decreased (44.7% to 11.2%; P<0.0001). The mean logistic EuroSCORE decreased significantly from 19.4±10.9% to 15.8±8.7% (P=0.01). The 30-day mortality rate did not change significantly (6.4% vs. 5.6%; P=0.99). Similarly, rates of major vascular complications (12.8% vs. 15.4%; P=0.87) and stroke (2.1% vs. 1.4%; P=0.75) remained unchanged. Mean length of stay after TAVI decreased significantly from 8.9±11.3 days to 4.8±4.7 days (P=0.002) and 72 (50.3%) patients were discharged early in 2013. One-year survival increased significantly from 81.0% to 94.4% (P=0.03).
CONCLUSIONS: Over the past 4 years, TAVI has been increasingly performed using a transfemoral approach. Treated patients are at lower-risk with less co-morbidity. Thirty-day mortality and complications remained unchanged, but length of stay after TAVI and 1-year mortality decreased dramatically.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Aortic stenosis; Rétrécissement aortique; TAVI; VARC-2

Mesh:

Year:  2016        PMID: 27342810     DOI: 10.1016/j.acvd.2016.01.016

Source DB:  PubMed          Journal:  Arch Cardiovasc Dis        ISSN: 1875-2128            Impact factor:   2.340


  5 in total

1.  Transcatheter aortic valve implantation at a high-volume center: the Bad Rothenfelde experience.

Authors:  Marek Kowalski; Cornelia Deutsch; Steffen Hofmann; Norbert Franz; Michael Billion; Abbas Ferdosi; Peter Bramlage; Guram Imnadze; Henning Warnecke
Journal:  Kardiochir Torakochirurgia Pol       Date:  2017-12-20

2.  One-Year Costs Associated with Hospitalizations Due to Aortic Stenosis in Canada.

Authors:  Jean-Eric Tarride; Sandra Lauck; Madhu K Natarajan; Anita W Asgar; Trinh Luong; Gord Blackhouse
Journal:  CJC Open       Date:  2020-09-19

3.  Temporal Trends of Transcatheter Aortic Valve Implantation over 12 Years: A High-Volume Single-Center Experience.

Authors:  Shir Frydman; David Zahler; Ilan Merdler; Ophir Freund; Yacov Shacham; Shmuel Banai; Ariel Finkelstein; Arie Steinvil
Journal:  J Clin Med       Date:  2022-08-24       Impact factor: 4.964

4.  Optimal antiplatelet strategy after transcatheter aortic valve implantation: a meta-analysis.

Authors:  Yousif Ahmad; Ozan Demir; Christopher Rajkumar; James P Howard; Matthew Shun-Shin; Christopher Cook; Ricardo Petraco; Richard Jabbour; Ahran Arnold; Angela Frame; Nilesh Sutaria; Ben Ariff; Gajen Kanaganayagam; Darrel Francis; Jamil Mayet; Ghada Mikhail; Iqbal Malik; Sayan Sen
Journal:  Open Heart       Date:  2018-01-26

5.  Differences in the presentation and management of patients with severe aortic stenosis in different European centres.

Authors:  Matthias Lutz; David Messika-Zeitoun; Tanja K Rudolph; Eberhard Schulz; Jeetendra Thambyrajah; Guy Lloyd; Alexander Lauten; Norbert Frey; Jana Kurucova; Martin Thoenes; Cornelia Deutsch; Peter Bramlage; Richard Paul Steeds
Journal:  Open Heart       Date:  2020-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.